Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Non-Hodgkin lymphoma

  • Home
  • Non-Hodgkin lymphoma
Preclinical Progress of Glofitamab Combinations: Pioneering Therapeutics in Non-Hodgkin Lymphoma Management
Posted inHematology-Oncology news Oncology

Preclinical Progress of Glofitamab Combinations: Pioneering Therapeutics in Non-Hodgkin Lymphoma Management

Posted by MedXY By MedXY 10/14/2025
Glofitamab, a CD20×CD3 T-cell engager, demonstrates promising synergistic effects in combination with chemotherapy and novel immunotherapies, addressing resistance mechanisms in non-Hodgkin lymphoma preclinical models and supporting future clinical investigation.
Read More
Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients
Posted inAllergy & Immunology Hematology-Oncology Specialties

Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients

Posted by MedXY By MedXY 08/29/2025
Clonal hematopoiesis (CH) occurs frequently in patients receiving CD19 or BCMA CAR T therapy and correlates with a higher risk of severe cytokine release syndrome (CRS), suggesting CH as a potential biomarker for CRS risk and a target for prophylactic strategies.
Read More
  • Long-Term Exposure to PM2.5 Constituents and Coronary Heart Disease Risk in China: A Comprehensive Review
  • Impact of Medically Tailored Groceries on Glycemic Control in Medicaid-Insured Adults with Type 2 Diabetes: Insights from a Randomized Controlled Trial
  • Digital Standardized Skin Care Regimen Enhances Outcomes in Patients with Acne-Rosacea Comorbidity: Insights from a Real-World Longitudinal Cohort
  • What Lies Beneath: Navigating Carotid Artery Depth for Safe Hemostatic Net Use in Facelift Surgery
  • Clarifying Dorsal Preservation Rhinoplasty: Insights and Classification from Over a Thousand Cases
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in